A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer
A study for patients with LIV-1-positive metastatic breast cancer using study drug SGN-LIV1A
Sponsor: Seattle Genetics, Inc
Enrolling: Female Patients Only
IRB Number: AAAQ9893
U.S. Govt. ID: NCT01969643
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out what side effects (unwanted effects) are caused in patients with breast cancer who are given SGN-LIV1A (single therapy). This study will also look at other effects of SGN-LIV1A, including its effect on this type of cancer. This study is also being done to find out what side effects (unwanted effects) are caused in patients with HER2-positive breast cancer who are given SGN-LIV1A in combination with trastuzumab (combination therapy). SGN-LIV1A has been given to animals, but has never been given to humans before this study.
This study is closed
Investigator
Kevin Kalinsky, MD, MS
Do You Qualify?
Have you been diagnosed with breast cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE